- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Interventions
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 6,919
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
- Interventions
- Pristine™ Long-Term Hemodialysis Catheter
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 6
- States / cities
- Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
- Conditions
- Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
- Interventions
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Months to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- End Stage Renal Disease
- Interventions
- Transplant navigator, Usual care
- Behavioral
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- End Stage Renal Disease
- Interventions
- Expanded AD Choice, Expanded Life-sustaining Therapy Choice
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Camden, New Jersey • Philadelphia, Pennsylvania • Radnor, Pennsylvania + 1 more
- Conditions
- Diabetic Kidney Disease
- Interventions
- Pentoxifylline, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 2,376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 31 more
- Conditions
- Urinary Incontinence, Cystic Fibrosis
- Interventions
- Reusable Underwear, Disposable urethral support, Pelvic floor physical therapy
- Device · Behavioral
- Lead sponsor
- Megan Bradley
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Kidney Diseases, Kidney Failure
- Interventions
- Training
- Other
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Beverly, Massachusetts • Waltham, Massachusetts
- Conditions
- Hyperphosphatemia
- Interventions
- Niacinamide, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Surgeries Undergoing General Anesthesia
- Interventions
- Lower FiO2, Intermediate FiO2, Higher FiO2
- Other
- Lead sponsor
- Frederic T Billings IV
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Omaha, Nebraska • Nashville, Tennessee + 1 more
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Urinary Incontinence
- Interventions
- Bladder Health Class
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
- Interventions
- solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more
- Conditions
- Overactive Bladder
- Interventions
- (VERV™ System), Sham version of (VERV™ System)
- Device
- Lead sponsor
- Ethicon Endo-Surgery
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Overactive Bladder (OAB)
- Interventions
- FemPulse System
- Device
- Lead sponsor
- FemPulse Corporation
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Fort Lauderdale, Florida
- Conditions
- Kidney Transplantation, Kidney Failure, Chronic
- Interventions
- Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 888 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 103
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
- Conditions
- Urinary Bladder, Overactive, Spinal Cord Injury
- Interventions
- Urodynamics, EG110A, Patient-reported Outcome
- Other · Drug
- Lead sponsor
- Cyllene Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Downey, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Interventions
- Biospecimen collection, Data collection
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Primary IgA Nephropathy
- Interventions
- Nefecon, Placebo oral capsule
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
- Conditions
- Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
- Interventions
- Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
- Drug · Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Diabetic Kidney Disease
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
- Conditions
- Acute Kidney Injury, Immune Deficiency
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- AZD0120, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- San Francisco, California • Stanford, California • Tampa, Florida + 11 more